Finally, while the study predominantly focused on pleural effusion, it also validated that the sHLA immunopeptidome can serve as a valuable source of TAAs as evidenced by the identification of several known TAAs (SAGE1, PBK and ODF2) in both pleural effusion and plasma samples of lung cancer patients. This evidence concerns the gene ODF2 and Pleural effusion.